Mankind Pharma Q3 FY26 earnings call: Revenue & Margins
Q3 FY26 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹3,567Cr
- +11.5% YoY
- −3.5% QoQ
- Net profit
- ₹414Cr
- +7.5% YoY
- −20.4% QoQ
- Margin
- 26%
- 0 pp YoY
- +1 pp QoQ
Guidance rank: #61 of 87 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
The short version
Anti-infective segment expected to grow quarter-on-quarter as team stability and doctor relationships improve, despite past underperformance. Mankind Pharma expects consistent quarter-on-quarter growth in anti-infectives going forward after a correction phase of 15-18 months.
From Mankind Pharma's Q3 FY26 earnings-call transcript · updated 26 Aug 2026.
Revenue & Sales Performance
- Anti-infective segment expected to grow quarter-on-quarter as team stability and doctor relationships improve, despite past underperformance.
- Overall domestic prescription business growth for Q3 was 9%+ and 8.2% for 9 months (excluding OTC), indicating steady growth.
- Chronic and other non-acute therapies show strong quarter-on-quarter growth of 12-15%, outperforming industry averages.
- Export business grew 14% YoY in Q3 and 51% in 9 months, with EU GMP certification enhancing capabilities.
- OTC business saw improved performance with 5.2% YoY growth in Q3 and 5.6% in 9 months; modern trade and e-commerce channels growing 30-40%.
2 more points from Mankind Pharma's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Mankind Pharma said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Mankind Pharma said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Mankind Pharma said on order book & pipeline — free account, 30 seconds.
Mankind Pharma — Quarterly revenue & net profit
Mankind Pharma Q3 FY26 results — key figures
| ₹ Cr | Q3 FY26 | Q3 FY25 | YoY | Q2 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 3,567 | 3,199 | +11.5% | 3,697 | -3.5% |
| Operating profit (EBITDA) | 919 | 816 | +12.6% | 921 | -0.2% |
| Operating margin | 26% | 26% | 0 pp | 25% | +1 pp |
| Profit before tax | 509 | 495 | +2.8% | 624 | -18.4% |
| Net profit (PAT) | 414 | 385 | +7.5% | 520 | -20.4% |
| EPS (₹) | 9.90 | 9.22 | +7.4% | 12.39 | -20.1% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹4.3K Cr, net profit ₹716 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Mankind Pharma's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Natural Capsules (Q3 FY26)
Q3FY26 revenue from operations: ₹37.75 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q3 FY26 investor presentation — and how it ranks
- Wanbury (Q3 FY26)
Q3FY26 Revenue from Operations: ₹162.45 Crore . Key investor presentation takeaways from Wanbury Ltd's Q3 FY26 investor presentation — and how it ranks against
- Gujarat Themis Biosyn (Q3 FY26)
43.37 crore, up 9.74% YoY from Rs. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q3 FY26 investor presentation — and how it ranks against
- Balaxi Pharma (Q3 FY26)
Q3 FY26 revenue: ₹72.54 crore, down marginally by 1% YoY from ₹73.29 crore in Q3 FY25 (Page 19). Key investor presentation takeaways from Balaxi Pharma's Q3 FY2
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Mankind Pharma and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Mankind Pharma Q3 FY26 results?
Anti-infective segment expected to grow quarter-on-quarter as team stability and doctor relationships improve, despite past underperformance. Mankind Pharma expects consistent quarter-on-quarter growth in anti-infectives going forward after a correction phase of 15-18 months.
What is Mankind Pharma share price analysis?
Mankind Pharma currently shows a neutral. The stock trades at a P/E of 46.2 with a market cap of ₹98,458 Cr. Investors should review the full earnings analysis for detailed insights.
Is Mankind Pharma planning capital expenditure?
The company's incremental capex spend for the quarter was under INR 200 crores.
Keep Mankind Pharma on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
